Sugi Predict

Sugi Predict / Compounds / SCHEMBL305392

SCHEMBL305392

SCHEMBL305392

O=C(CCc1ccc(O)cc1)OCc1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.68
▸ ALDH1A1 P00352 3/20 0.58
▸ MAPK1 P28482 2/20 0.58
▸ L3MBTL1 Q9Y468 2/20 0.58
▸ APP P05067 1/20 0.57
▸ LMNA P02545 1/20 0.57
▸ FFAR1 O14842 2/20 0.53
▸ FFAR4 Q5NUL3 1/20 0.53
▸ ESR1 P03372 1/20 0.53
▸ ESR2 Q92731 1/20 0.53
▸ TRPV1 Q8NER1 1/20 0.51
▸ CASP1 P29466 1/20 0.51
▸ CYP19A1 P11511 1/20 0.50
▸ ALOX5 P09917 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL304176 0.93 TDP1 (0.78) TDP1ALDH1A1MAPK1L3MBTL1APP
Ammonia Solution, Strong SCHEMBL28588274 0.91 TDP1 (0.75) TDP1ALDH1A1MAPK1L3MBTL1APP
SCHEMBL28207503 0.91 TDP1 (0.75) TDP1ALDH1A1MAPK1L3MBTL1APP
Bicarbonate SCHEMBL7699565 0.91 TDP1 (0.75) TDP1ALDH1A1MAPK1L3MBTL1APP
SCHEMBL14793821 0.90 TRPV1 (0.57) TDP1ALDH1A1MAPK1L3MBTL1LMNA
SCHEMBL3708328 0.88 TDP1 (0.66) TDP1ALDH1A1MAPK1L3MBTL1APP
SCHEMBL22162624 0.87 TDP1 (0.64) TDP1ALDH1A1MAPK1L3MBTL1APP
SCHEMBL20824921 0.87 TDP1 (0.64) TDP1ALDH1A1MAPK1L3MBTL1APP
SCHEMBL28450115 0.87 TDP1 (0.64) TDP1ALDH1A1MAPK1L3MBTL1APP
SCHEMBL6159752 0.87 TDP1 (0.64) TDP1ALDH1A1MAPK1L3MBTL1APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12571023-B2 Composition and methods for affinity directed enrichment of rare species SPARK MOLECULAR DIAGNOSTICS, INC. (US) 2026-03-10 — — US disclosed
US-20210139976-A1 NUCLEOTIDE ANALOGUES AND USE THEREOF FOR NUCLEIC ACID SEQUENCING AND ANALYSIS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2021-05-13 — — US disclosed
CN-112400026-A Compositions and methods for affinity directed enrichment of rare species CY分子诊断公司 2021-02-23 — — CN disclosed
US-20200399683-A1 Composition and Methods For Affinity Directed Enrichment of Rare Species SPARK MOLECULAR DIAGNOSTICS, INC. 2020-12-24 — — US disclosed
US-20200399683-A1 Composition and Methods For Affinity Directed Enrichment of Rare Species SPARK MOLECULAR DIAGNOSTICS, INC. 2020-12-24 — — US disclosed
EP-3746567-A1 COMPOSITION AND METHODS FOR AFFINITY DIRECTED ENRICHMENT OF RARE SPECIES CY Molecular Diagnostics, Inc (US) 2020-12-09 — — EP disclosed
WO-2019165469-A1 COMPOSITION AND METHODS FOR AFFINITY DIRECTED ENRICHMENT OF RARE SPECIES CY MOLECULAR DIAGNOSTICS, INC (US) 2019-08-29 — — WO disclosed
WO-2017116702-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS MERIAL, INC. (US) 2017-07-06 — — WO disclosed
US-20170143705-A1 PYRAZINE DERIVATIVES AS ENAC BLOCKERS NOVARTIS AG (CH) 2017-05-25 — — US disclosed
US-9522149-B2 Pyrazine derivatives as ENaC blockers NOVARTIS AG (CH) 2016-12-20 — — US disclosed
EP-0858457-A1 5-MEMBERED HETEROCYCLES, PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF AND METHODS OF PRODUCING THEM Dr. Karl Thomae GmbH (DE) 1998-08-19 — — EP disclosed
US-5756011-A CHEMILUMINESCENT REACTIONS GEN-PROBE INCORPORATED (US) 1998-05-26 — — US disclosed
US-5656207-A CHEMILUMINESCENCE ASSAY GEN PROBE INCORPORATED 1997-08-12 — — US disclosed
WO-1997015567-A1 5-MEMBERED HETEROCYCLES, PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF AND METHODS OF PRODUCING THEM DR. KARL THOMAE GMBH (DE) 1997-05-01 — — WO disclosed
EP-0478626-B1 DETECTING OR QUANTIFYING MULTIPLE ANALYTES USING LABELLING TECHNIQUES GEN PROBE INC (US) 1996-01-17 — — EP disclosed
US-5321136-A Peri substituted fused ring chemiluminescent labels and their conjugates, and assays therefrom LONDON DIAGNOSTICS, INC. (US) 1994-06-14 — — US disclosed
EP-0478626-A1 DETECTING OR QUANTIFYING MULTIPLE ANALYTES USING LABELLING TECHNIQUES. UNIV WALES MEDICINE (GB) 1992-04-08 — — EP disclosed
WO-1991000511-A1 DETECTING OR QUANTIFYING MULTIPLE ANALYTES USING LABELLING TECHNIQUES UNIVERSITY OF WALES COLLEGE OF MEDICINE (GB) 1991-01-10 — — WO disclosed
US-4348410-A Cyclohexane carboxylic acid derivatives NIPPON CHEMIPHAR CO., LTD. (JP) 1982-09-07 — — US disclosed
US-4147876-A CHEMICAL INTERMEDIATE FOR ANTIULCER AGENTS AND ENZYME INHIBITORS DAIICHI SEIYAKU CO., LTD. (JP) 1979-04-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12571023-B2 Composition and methods for affinity directed enrichment of rare species CPSF6, CPSF1, NUDT21 TDP1 68/4885ALDH1A1 3476/4885MAPK1 4341/4885
US-20170143705-A1 PYRAZINE DERIVATIVES AS ENAC BLOCKERS REN, SCNN1B, SCN5A TDP1 4306/4885ALDH1A1 2428/4885MAPK1 2369/4885
US-20210139976-A1 NUCLEOTIDE ANALOGUES AND USE THEREOF FOR NUCLEIC ACID SEQUENCING AND ANALYSIS NUDT1, NT5C3B, RNGTT TDP1 465/4885ALDH1A1 2942/4885MAPK1 3978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.